Tanida, Kotomi
Shimada, Mihoko
Khor, Seik-Soon
Toyoda, Hiromi
Kato, Kayoko
Kotorii, Nozomu
Kotorii, Tatayu
Ariyoshi, Yu
Kato, Takao
Hiejima, Hiroshi
Ozone, Motohiro
Uchimura, Naohisa
Ikegami, Azusa
Kume, Kazuhiko
Kanbayashi, Takashi
Imanishi, Aya
Kamei, Yuichi
Hida, Akiko
Wada, Yamato
Kuroda, Kenji
Miyamoto, Masayuki
Hirata, Koichi
Takami, Masanori
Yamada, Naoto
Okawa, Masako
Omata, Naoto
Kondo, Hideaki
Kodama, Tohru
Inoue, Yuichi
Mishima, Kazuo
Honda, Makoto
Tokunaga, Katsushi
Miyagawa, Taku http://orcid.org/0000-0002-9466-9420
Funding for this research was provided by:
Japan Society for the Promotion of Science (15H04709, 19H03588, 21K07534)
Japan Agency for Medical Research and Development (Practical Research Project for Rare/Intractable Diseases grant)
Takeda Science Foundation
Article History
Received: 4 June 2021
Accepted: 20 September 2021
First Online: 12 October 2021
Declarations
:
: Dr. Inoue Yuichi has received grants and payment for lectures, including service on speakers’ bureaus, and has provided expert testimony for MSD K.K., Takeda Pharmaceutical Co. Ltd., and Eisai Co. Ltd. Dr. Makoto Honda has received consulting fees from Takeda Pharmaceutical Co. Ltd. The other authors have no competing interests to declare.
: This research involved human participants. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. All individuals provided written informed consent for participation in this study.